Microfluidics As Tool to Prepare Size-tunable PLGA Nanoparticles with High Curcumin Encapsulation for Efficient Mucus Penetration

Overview

Journal Beilstein J Nanotechnol

Specialty Biotechnology

Date 2019 Dec 7

PMID 31807413

Citations 18

Authors

Nashrawan Lababidi

Valentin Sigal

Aljoscha Koenneke

Konrad Schwarzkopf

Andreas Manz

Marc Schneider

Affiliations

Soon will be listed here.

Abstract

Great challenges still remain to develop drug carriers able to penetrate biological barriers (such as the dense mucus in cystic fibrosis) and for the treatment of bacteria residing in biofilms, embedded in mucus. Drug carrier systems such as nanoparticles (NPs) require proper surface chemistry and small size to ensure their permeability through the hydrogel-like systems. We have employed a microfluidic system to fabricate poly(lactic--glycolic acid) (PLGA) nanoparticles coated with a muco-penetrating stabilizer (Pluronic), with a tunable hydrodynamic diameter ranging from 40 nm to 160 nm. The size dependence was evaluated by varying different parameters during preparation, namely polymer concentration, stabilizer concentration, solvent nature, the width of the focus mixing channel, flow rate ratio and total flow rate. Furthermore, the influence of the length of the focus mixing channel on the size was evaluated in order to better understand the nucleation-growth mechanism. Surprisingly, the channel length was revealed to have no effect on particle size for the chosen settings. In addition, curcumin was loaded (EE% of ≈68%) very efficiently into the nanoparticles. Finally, the permeability of muco-penetrating PLGA NPs through pulmonary human mucus was assessed; small NPs with a diameter of less than 100 nm showed fast permeation, underlining the potential of microfluidics for such pharmaceutical applications.

Citing Articles

Global scenario of silica-associated diseases: A review on emerging pathophysiology of silicosis and potential therapeutic regimes.

Sherekar P, Suke S, Dhok A, Malegaonkar S, Dhale S Toxicol Rep. 2025; 14:101941.

PMID: 39989982 PMC: 11847043. DOI: 10.1016/j.toxrep.2025.101941.

Scalable Manufacturing Method for Model Protein-Loaded PLGA Nanoparticles: Biocompatibility, Trafficking and Release Properties.

Akpinar Adscheid S, Rojas-Rodriguez M, Abdel-Hafez S, Pavone F, Schneider M, Tureli A Pharmaceutics. 2025; 17(1).

PMID: 39861735 PMC: 11768205. DOI: 10.3390/pharmaceutics17010087.

A Versatile, Low-Cost Modular Microfluidic System to Prepare Poly(Lactic-co-Glycolic Acid) Nanoparticles With Encapsulated Protein.

Neustrup M, Ottenhoff T, Jiskoot W, Bouwstra J, van der Maaden K Pharm Res. 2024; 41(12):2347-2361.

PMID: 39601944 PMC: 11682010. DOI: 10.1007/s11095-024-03792-1.

Poly(lactic-co-glycolic acid) nanoparticle fabrication, functionalization, and biological considerations for drug delivery.

Marecki E, Oh K, Knight P, Davidson B Biomicrofluidics. 2024; 18(5):051503.

PMID: 39296325 PMC: 11410388. DOI: 10.1063/5.0201465.

Elasticity, an often-overseen parameter in the development of nanoscale drug delivery systems.

Weiss A, Schneider M Beilstein J Nanotechnol. 2023; 14:1149-1156.

PMID: 38034475 PMC: 10682522. DOI: 10.3762/bjnano.14.95.

References

Niemeyer C . Nanoparticles, Proteins, and Nucleic Acids: Biotechnology Meets Materials Science. Angew Chem Int Ed Engl. 2018; 40(22):4128-4158. DOI: 10.1002/1521-3773(20011119)40:22<4128::AID-ANIE4128>3.0.CO;2-S. View

Nikoubashman A, Lee V, Sosa C, Prudhomme R, Priestley R, Panagiotopoulos A . Directed Assembly of Soft Colloids through Rapid Solvent Exchange. ACS Nano. 2015; 10(1):1425-33. DOI: 10.1021/acsnano.5b06890. View

Singh M, Chakrapani A, OHagan D . Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines. 2007; 6(5):797-808. DOI: 10.1586/14760584.6.5.797. View

Schneider M, Barozzi S, Testa I, Faretta M, Diaspro A . Two-photon activation and excitation properties of PA-GFP in the 720-920-nm region. Biophys J. 2005; 89(2):1346-52. PMC: 1366619. DOI: 10.1529/biophysj.104.054502. View

Zambaux M, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso M . Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Control Release. 1998; 50(1-3):31-40. DOI: 10.1016/s0168-3659(97)00106-5. View

Griesser J, Hetenyi G, Federer C, Steinbring C, Ellemunter H, Niedermayr K . Highly mucus permeating and zeta potential changing self-emulsifying drug delivery systems: A potent gene delivery model for causal treatment of cystic fibrosis. Int J Pharm. 2018; 557:124-134. DOI: 10.1016/j.ijpharm.2018.12.048. View

Ensign L, Lai S, Wang Y, Yang M, Mert O, Hanes J . Pretreatment of human cervicovaginal mucus with pluronic F127 enhances nanoparticle penetration without compromising mucus barrier properties to herpes simplex virus. Biomacromolecules. 2014; 15(12):4403-9. PMC: 4261994. DOI: 10.1021/bm501419z. View

Wong H, Bendayan R, Rauth A, Li Y, Wu X . Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev. 2007; 59(6):491-504. DOI: 10.1016/j.addr.2007.04.008. View

Ding S, Anton N, Vandamme T, Serra C . Microfluidic nanoprecipitation systems for preparing pure drug or polymeric drug loaded nanoparticles: an overview. Expert Opin Drug Deliv. 2016; 13(10):1447-60. DOI: 10.1080/17425247.2016.1193151. View

10.

Markwalter C, Pagels R, Wilson B, Ristroph K, Prudhomme R . Flash NanoPrecipitation for the Encapsulation of Hydrophobic and Hydrophilic Compounds in Polymeric Nanoparticles. J Vis Exp. 2019; (143). DOI: 10.3791/58757. View

11.

DAddio S, Prudhomme R . Controlling drug nanoparticle formation by rapid precipitation. Adv Drug Deliv Rev. 2011; 63(6):417-26. DOI: 10.1016/j.addr.2011.04.005. View

12.

Witten J, Samad T, Ribbeck K . Selective permeability of mucus barriers. Curr Opin Biotechnol. 2018; 52:124-133. PMC: 7132988. DOI: 10.1016/j.copbio.2018.03.010. View

13.

Lai S, Wang Y, Hanes J . Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009; 61(2):158-71. PMC: 2667119. DOI: 10.1016/j.addr.2008.11.002. View

14.

Tang B, Dawson M, Lai S, Wang Y, Suk J, Yang M . Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci U S A. 2009; 106(46):19268-73. PMC: 2780804. DOI: 10.1073/pnas.0905998106. View

15.

Gunday Tureli N, Tureli A, Schneider M . Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: Design of experiments approach. Int J Pharm. 2016; 515(1-2):343-351. DOI: 10.1016/j.ijpharm.2016.10.025. View

16.

Zhao L, Seth A, Wibowo N, Zhao C, Mitter N, Yu C . Nanoparticle vaccines. Vaccine. 2013; 32(3):327-37. DOI: 10.1016/j.vaccine.2013.11.069. View

17.

Davis M, Chen Z, Shin D . Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7(9):771-82. DOI: 10.1038/nrd2614. View

18.

Netsomboon K, Bernkop-Schnurch A . Mucoadhesive vs. mucopenetrating particulate drug delivery. Eur J Pharm Biopharm. 2015; 98:76-89. DOI: 10.1016/j.ejpb.2015.11.003. View

19.

Forrest M, Kwon G . Clinical developments in drug delivery nanotechnology. Adv Drug Deliv Rev. 2008; 60(8):861-2. DOI: 10.1016/j.addr.2008.02.013. View

20.

Lai S, OHanlon D, Harrold S, Man S, Wang Y, Cone R . Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A. 2007; 104(5):1482-7. PMC: 1785284. DOI: 10.1073/pnas.0608611104. View